APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-benzodiazepine Hypnotics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Non-benzodiazepine Hypnotics Market Outlook and Growth Opportunities 2026

30 December 2025218 pages

Choose your research edition.

Industry ResearchNon-benzodiazepine Hypnotics Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-benzodiazepine Hypnotics Industry Growth and Trends Forecast to 2032128 pages · $3,450 USDMarket StructureGlobal Non-benzodiazepine Hypnotics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-benzodiazepine Hypnotics Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Non-benzodiazepine Hypnotics Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Non-benzodiazepine Hypnotics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Non-benzodiazepine Hypnotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non-benzodiazepine Hypnotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-benzodiazepine Hypnotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Non-benzodiazepine Hypnotics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Non-benzodiazepine Hypnotics market include Abbott, Tianjin Tasly Saint Pharmaceuticals, Sun Pharmaceutical, Shanghai Pharmaceuticals, Qilu Pharmaceutical, Kanghong Pharmaceuticals, Changzhou Siyao Pharmaceutical, Wockhardt and Torrent Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Non-benzodiazepine Hypnotics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non-benzodiazepine Hypnotics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non-benzodiazepine Hypnotics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Non-benzodiazepine Hypnotics market size, projected growth trends, production technologies, key applications, and end-use industries.

Non-benzodiazepine Hypnotics Segment by Company

Abbott

Tianjin Tasly Saint Pharmaceuticals

Sun Pharmaceutical

Shanghai Pharmaceuticals

Qilu Pharmaceutical

Kanghong Pharmaceuticals

Changzhou Siyao Pharmaceutical

Wockhardt

Torrent Pharma

Teva Pharmaceuticals

Tapi Teva

Sanofi-aventis

Northstar Rx

Mylan Pharmaceuticals

Kanghong Pharmaceutical

Hikma Pharmaceuticals

Glenmark Life Sciences

Endo

Dr. Reddy’s Laboratories

Centaur Pharmaceuticals

Apotex

Admiron Life

Non-benzodiazepine Hypnotics Segment by Type

Zaleplon

Zopiclone

Zolpidem

Other

Non-benzodiazepine Hypnotics Segment by Application

Hospital

Clinic

Other

Non-benzodiazepine Hypnotics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Non-benzodiazepine Hypnotics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Non-benzodiazepine Hypnotics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Non-benzodiazepine Hypnotics significant trends, drivers, influence factors in global and regions.

6. To analyze Non-benzodiazepine Hypnotics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-benzodiazepine Hypnotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-benzodiazepine Hypnotics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-benzodiazepine Hypnotics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Non-benzodiazepine Hypnotics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-benzodiazepine Hypnotics industry.

Chapter 3: Detailed analysis of Non-benzodiazepine Hypnotics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Non-benzodiazepine Hypnotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Non-benzodiazepine Hypnotics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Non-benzodiazepine Hypnotics Industry Trends Table 2. Non-benzodiazepine Hypnotics Industry Drivers Table 3. Non-benzodiazepine Hypnotics Industry Opportunities and Challenges Table 4. Non-benzodiazepine Hypnotics Industry Restraints Table 5. Global Non-benzodiazepine Hypnotics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Non-benzodiazepine Hypnotics Revenue Share by Company (2021-2026) Table 7. Global Non-benzodiazepine Hypnotics Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Non-benzodiazepine Hypnotics Sales Volume Share by Company (2021-2026) Table 9. Global Non-benzodiazepine Hypnotics Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Non-benzodiazepine Hypnotics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Non-benzodiazepine Hypnotics Key Company Manufacturing Base & Headquarters Table 12. Global Non-benzodiazepine Hypnotics Company, Product Type & Application Table 13. Global Non-benzodiazepine Hypnotics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Non-benzodiazepine Hypnotics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Zaleplon Table 18. Significant Companies of Zopiclone Table 19. Significant Companies of Zolpidem Table 20. Significant Companies of Other Table 21. Global Non-benzodiazepine Hypnotics Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Non-benzodiazepine Hypnotics Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Non-benzodiazepine Hypnotics Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Non-benzodiazepine Hypnotics Sales Volume Share by Type (2021-2026) Table 25. Global Non-benzodiazepine Hypnotics Sales Volume Share by Type (2027-2032) Table 26. Global Non-benzodiazepine Hypnotics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Non-benzodiazepine Hypnotics Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Non-benzodiazepine Hypnotics Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Non-benzodiazepine Hypnotics Sales Value Share by Type (2021-2026) Table 30. Global Non-benzodiazepine Hypnotics Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Other Table 34. Global Non-benzodiazepine Hypnotics Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Non-benzodiazepine Hypnotics Sales Volume by Application (2021-2026) & (K Units) Table 36. Global Non-benzodiazepine Hypnotics Sales Volume by Application (2027-2032) & (K Units) Table 37. Global Non-benzodiazepine Hypnotics Sales Volume Share by Application (2021-2026) Table 38. Global Non-benzodiazepine Hypnotics Sales Volume Share by Application (2027-2032) Table 39. Global Non-benzodiazepine Hypnotics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Non-benzodiazepine Hypnotics Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Non-benzodiazepine Hypnotics Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Non-benzodiazepine Hypnotics Sales Value Share by Application (2021-2026) Table 43. Global Non-benzodiazepine Hypnotics Sales Value Share by Application (2027-2032) Table 44. Global Non-benzodiazepine Hypnotics Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Non-benzodiazepine Hypnotics Sales by Region (2021-2026) & (K Units) Table 46. Global Non-benzodiazepine Hypnotics Sales Market Share by Region (2021-2026) Table 47. Global Non-benzodiazepine Hypnotics Sales by Region (2027-2032) & (K Units) Table 48. Global Non-benzodiazepine Hypnotics Sales Market Share by Region (2027-2032) Table 49. Global Non-benzodiazepine Hypnotics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Non-benzodiazepine Hypnotics Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Non-benzodiazepine Hypnotics Sales Value Share by Region (2021-2026) Table 52. Global Non-benzodiazepine Hypnotics Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Non-benzodiazepine Hypnotics Sales Value Share by Region (2027-2032) Table 54. Global Non-benzodiazepine Hypnotics Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Non-benzodiazepine Hypnotics Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Non-benzodiazepine Hypnotics Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Global Non-benzodiazepine Hypnotics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Non-benzodiazepine Hypnotics Sales by Country (2021-2026) & (K Units) Table 59. Global Non-benzodiazepine Hypnotics Sales Market Share by Country (2021-2026) Table 60. Global Non-benzodiazepine Hypnotics Sales by Country (2027-2032) & (K Units) Table 61. Global Non-benzodiazepine Hypnotics Sales Market Share by Country (2027-2032) Table 62. Global Non-benzodiazepine Hypnotics Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Non-benzodiazepine Hypnotics Sales Value Market Share by Country (2021-2026) Table 64. Global Non-benzodiazepine Hypnotics Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Non-benzodiazepine Hypnotics Sales Value Market Share by Country (2027-2032) Table 66. Abbott Company Information Table 67. Abbott Business Overview Table 68. Abbott Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Abbott Non-benzodiazepine Hypnotics Product Portfolio Table 70. Abbott Recent Development Table 71. Tianjin Tasly Saint Pharmaceuticals Company Information Table 72. Tianjin Tasly Saint Pharmaceuticals Business Overview Table 73. Tianjin Tasly Saint Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Tianjin Tasly Saint Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 75. Tianjin Tasly Saint Pharmaceuticals Recent Development Table 76. Sun Pharmaceutical Company Information Table 77. Sun Pharmaceutical Business Overview Table 78. Sun Pharmaceutical Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Sun Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio Table 80. Sun Pharmaceutical Recent Development Table 81. Shanghai Pharmaceuticals Company Information Table 82. Shanghai Pharmaceuticals Business Overview Table 83. Shanghai Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Shanghai Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 85. Shanghai Pharmaceuticals Recent Development Table 86. Qilu Pharmaceutical Company Information Table 87. Qilu Pharmaceutical Business Overview Table 88. Qilu Pharmaceutical Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Qilu Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio Table 90. Qilu Pharmaceutical Recent Development Table 91. Kanghong Pharmaceuticals Company Information Table 92. Kanghong Pharmaceuticals Business Overview Table 93. Kanghong Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Kanghong Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 95. Kanghong Pharmaceuticals Recent Development Table 96. Changzhou Siyao Pharmaceutical Company Information Table 97. Changzhou Siyao Pharmaceutical Business Overview Table 98. Changzhou Siyao Pharmaceutical Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Changzhou Siyao Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio Table 100. Changzhou Siyao Pharmaceutical Recent Development Table 101. Wockhardt Company Information Table 102. Wockhardt Business Overview Table 103. Wockhardt Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Wockhardt Non-benzodiazepine Hypnotics Product Portfolio Table 105. Wockhardt Recent Development Table 106. Torrent Pharma Company Information Table 107. Torrent Pharma Business Overview Table 108. Torrent Pharma Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Torrent Pharma Non-benzodiazepine Hypnotics Product Portfolio Table 110. Torrent Pharma Recent Development Table 111. Teva Pharmaceuticals Company Information Table 112. Teva Pharmaceuticals Business Overview Table 113. Teva Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Teva Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 115. Teva Pharmaceuticals Recent Development Table 116. Tapi Teva Company Information Table 117. Tapi Teva Business Overview Table 118. Tapi Teva Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Tapi Teva Non-benzodiazepine Hypnotics Product Portfolio Table 120. Tapi Teva Recent Development Table 121. Sanofi-aventis Company Information Table 122. Sanofi-aventis Business Overview Table 123. Sanofi-aventis Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Sanofi-aventis Non-benzodiazepine Hypnotics Product Portfolio Table 125. Sanofi-aventis Recent Development Table 126. Northstar Rx Company Information Table 127. Northstar Rx Business Overview Table 128. Northstar Rx Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Northstar Rx Non-benzodiazepine Hypnotics Product Portfolio Table 130. Northstar Rx Recent Development Table 131. Mylan Pharmaceuticals Company Information Table 132. Mylan Pharmaceuticals Business Overview Table 133. Mylan Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Mylan Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 135. Mylan Pharmaceuticals Recent Development Table 136. Kanghong Pharmaceutical Company Information Table 137. Kanghong Pharmaceutical Business Overview Table 138. Kanghong Pharmaceutical Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Kanghong Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio Table 140. Kanghong Pharmaceutical Recent Development Table 141. Hikma Pharmaceuticals Company Information Table 142. Hikma Pharmaceuticals Business Overview Table 143. Hikma Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Hikma Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 145. Hikma Pharmaceuticals Recent Development Table 146. Glenmark Life Sciences Company Information Table 147. Glenmark Life Sciences Business Overview Table 148. Glenmark Life Sciences Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. Glenmark Life Sciences Non-benzodiazepine Hypnotics Product Portfolio Table 150. Glenmark Life Sciences Recent Development Table 151. Endo Company Information Table 152. Endo Business Overview Table 153. Endo Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Endo Non-benzodiazepine Hypnotics Product Portfolio Table 155. Endo Recent Development Table 156. Dr. Reddy’s Laboratories Company Information Table 157. Dr. Reddy’s Laboratories Business Overview Table 158. Dr. Reddy’s Laboratories Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Dr. Reddy’s Laboratories Non-benzodiazepine Hypnotics Product Portfolio Table 160. Dr. Reddy’s Laboratories Recent Development Table 161. Centaur Pharmaceuticals Company Information Table 162. Centaur Pharmaceuticals Business Overview Table 163. Centaur Pharmaceuticals Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 164. Centaur Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio Table 165. Centaur Pharmaceuticals Recent Development Table 166. Apotex Company Information Table 167. Apotex Business Overview Table 168. Apotex Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 169. Apotex Non-benzodiazepine Hypnotics Product Portfolio Table 170. Apotex Recent Development Table 171. Admiron Life Company Information Table 172. Admiron Life Business Overview Table 173. Admiron Life Non-benzodiazepine Hypnotics Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 174. Admiron Life Non-benzodiazepine Hypnotics Product Portfolio Table 175. Admiron Life Recent Development Table 176. Key Raw Materials Table 177. Raw Materials Key Suppliers Table 178. Non-benzodiazepine Hypnotics Distributors List Table 179. Non-benzodiazepine Hypnotics Customers List Table 180. Research Programs/Design for This Report Table 181. Authors List of This Report Table 182. Secondary Sources Table 183. Primary Sources List of Figures Figure 1. Non-benzodiazepine Hypnotics Product Image Figure 2. Global Non-benzodiazepine Hypnotics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-benzodiazepine Hypnotics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Non-benzodiazepine Hypnotics Sales (2021-2032) & (K Units) Figure 5. Global Non-benzodiazepine Hypnotics Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Non-benzodiazepine Hypnotics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Zaleplon Image Figure 10. Zopiclone Image Figure 11. Zolpidem Image Figure 12. Other Image Figure 13. Global Non-benzodiazepine Hypnotics Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Non-benzodiazepine Hypnotics Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Non-benzodiazepine Hypnotics Sales Volume Share by Type (2021-2032) Figure 16. Global Non-benzodiazepine Hypnotics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Non-benzodiazepine Hypnotics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Non-benzodiazepine Hypnotics Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Other Image Figure 22. Global Non-benzodiazepine Hypnotics Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Non-benzodiazepine Hypnotics Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Non-benzodiazepine Hypnotics Sales Volume Share by Application (2021-2032) Figure 25. Global Non-benzodiazepine Hypnotics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Non-benzodiazepine Hypnotics Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Non-benzodiazepine Hypnotics Sales Value Share by Application (2021-2032) Figure 28. Global Non-benzodiazepine Hypnotics Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 29. Global Non-benzodiazepine Hypnotics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Non-benzodiazepine Hypnotics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Non-benzodiazepine Hypnotics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Non-benzodiazepine Hypnotics Sales Value (2021-2032) & (US$ Million) Figure 33. North America Non-benzodiazepine Hypnotics Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Non-benzodiazepine Hypnotics Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Non-benzodiazepine Hypnotics Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Non-benzodiazepine Hypnotics Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Non-benzodiazepine Hypnotics Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Non-benzodiazepine Hypnotics Sales Value (2021-2032) & (US$ Million) Figure 39. South America Non-benzodiazepine Hypnotics Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Non-benzodiazepine Hypnotics Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Non-benzodiazepine Hypnotics Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Non-benzodiazepine Hypnotics Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Non-benzodiazepine Hypnotics Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Zaleplon
  • Zopiclone
  • Zolpidem
  • Other
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Abbott
  • Tianjin Tasly Saint Pharmaceuticals
  • Sun Pharmaceutical
  • Shanghai Pharmaceuticals
  • Qilu Pharmaceutical
  • Kanghong Pharmaceuticals
  • Changzhou Siyao Pharmaceutical
  • Wockhardt
  • Torrent Pharma
  • Teva Pharmaceuticals
  • Tapi Teva
  • Sanofi-aventis
  • Northstar Rx
  • Mylan Pharmaceuticals
  • Kanghong Pharmaceutical
  • Hikma Pharmaceuticals
  • Glenmark Life Sciences
  • Endo
  • Dr. Reddy’s Laboratories
  • Centaur Pharmaceuticals
  • Apotex
  • Admiron Life

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Non-benzodiazepine Hypnotics Sales Value (2021-2032)
  4. 1.2.2 Global Non-benzodiazepine Hypnotics Sales Volume (2021-2032)
  5. 1.2.3 Global Non-benzodiazepine Hypnotics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Non-benzodiazepine Hypnotics Market Dynamics
  1. 2.1 Non-benzodiazepine Hypnotics Industry Trends
  2. 2.2 Non-benzodiazepine Hypnotics Industry Drivers
  3. 2.3 Non-benzodiazepine Hypnotics Industry Opportunities and Challenges
  4. 2.4 Non-benzodiazepine Hypnotics Industry Restraints
3 Non-benzodiazepine Hypnotics Market by Company
  1. 3.1 Global Non-benzodiazepine Hypnotics Company Revenue Ranking in 2025
  2. 3.2 Global Non-benzodiazepine Hypnotics Revenue by Company (2021-2026)
  3. 3.3 Global Non-benzodiazepine Hypnotics Sales Volume by Company (2021-2026)
  4. 3.4 Global Non-benzodiazepine Hypnotics Average Price by Company (2021-2026)
  5. 3.5 Global Non-benzodiazepine Hypnotics Company Ranking (2024-2026)
  6. 3.6 Global Non-benzodiazepine Hypnotics Company Manufacturing Base and Headquarters
  7. 3.7 Global Non-benzodiazepine Hypnotics Company Product Type and Application
  8. 3.8 Global Non-benzodiazepine Hypnotics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Non-benzodiazepine Hypnotics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Non-benzodiazepine Hypnotics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Non-benzodiazepine Hypnotics Market by Type
  1. 4.1 Non-benzodiazepine Hypnotics Type Introduction
  2. 4.1.1 Zaleplon
  3. 4.1.2 Zopiclone
  4. 4.1.3 Zolpidem
  5. 4.1.4 Other
  6. 4.2 Global Non-benzodiazepine Hypnotics Sales Volume by Type
  7. 4.2.1 Global Non-benzodiazepine Hypnotics Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Non-benzodiazepine Hypnotics Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Non-benzodiazepine Hypnotics Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Non-benzodiazepine Hypnotics Sales Value by Type
  11. 4.3.1 Global Non-benzodiazepine Hypnotics Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Non-benzodiazepine Hypnotics Sales Value by Type (2021-2032)
  13. 4.3.3 Global Non-benzodiazepine Hypnotics Sales Value Share by Type (2021-2032)
5 Non-benzodiazepine Hypnotics Market by Application
  1. 5.1 Non-benzodiazepine Hypnotics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Non-benzodiazepine Hypnotics Sales Volume by Application
  6. 5.2.1 Global Non-benzodiazepine Hypnotics Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Non-benzodiazepine Hypnotics Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Non-benzodiazepine Hypnotics Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Non-benzodiazepine Hypnotics Sales Value by Application
  10. 5.3.1 Global Non-benzodiazepine Hypnotics Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Non-benzodiazepine Hypnotics Sales Value by Application (2021-2032)
  12. 5.3.3 Global Non-benzodiazepine Hypnotics Sales Value Share by Application (2021-2032)
6 Non-benzodiazepine Hypnotics Regional Sales and Value Analysis
  1. 6.1 Global Non-benzodiazepine Hypnotics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Non-benzodiazepine Hypnotics Sales by Region (2021-2032)
  3. 6.2.1 Global Non-benzodiazepine Hypnotics Sales by Region: 2021-2026
  4. 6.2.2 Global Non-benzodiazepine Hypnotics Sales by Region (2027-2032)
  5. 6.3 Global Non-benzodiazepine Hypnotics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Non-benzodiazepine Hypnotics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Non-benzodiazepine Hypnotics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Non-benzodiazepine Hypnotics Sales Value by Region (2027-2032)
  9. 6.5 Global Non-benzodiazepine Hypnotics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Non-benzodiazepine Hypnotics Sales Value (2021-2032)
  12. 6.6.2 North America Non-benzodiazepine Hypnotics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Non-benzodiazepine Hypnotics Sales Value (2021-2032)
  15. 6.7.2 Europe Non-benzodiazepine Hypnotics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Non-benzodiazepine Hypnotics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Non-benzodiazepine Hypnotics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Non-benzodiazepine Hypnotics Sales Value (2021-2032)
  21. 6.9.2 South America Non-benzodiazepine Hypnotics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Non-benzodiazepine Hypnotics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Non-benzodiazepine Hypnotics Sales Value Share by Country, 2025 VS 2032
7 Non-benzodiazepine Hypnotics Country-level Sales and Value Analysis
  1. 7.1 Global Non-benzodiazepine Hypnotics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Non-benzodiazepine Hypnotics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Non-benzodiazepine Hypnotics Sales by Country (2021-2032)
  4. 7.3.1 Global Non-benzodiazepine Hypnotics Sales by Country (2021-2026)
  5. 7.3.2 Global Non-benzodiazepine Hypnotics Sales by Country (2027-2032)
  6. 7.4 Global Non-benzodiazepine Hypnotics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Non-benzodiazepine Hypnotics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Non-benzodiazepine Hypnotics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Non-benzodiazepine Hypnotics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Non-benzodiazepine Hypnotics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Non-benzodiazepine Hypnotics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Non-benzodiazepine Hypnotics Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Tianjin Tasly Saint Pharmaceuticals
  8. 8.2.1 Tianjin Tasly Saint Pharmaceuticals Company Information
  9. 8.2.2 Tianjin Tasly Saint Pharmaceuticals Business Overview
  10. 8.2.3 Tianjin Tasly Saint Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Tianjin Tasly Saint Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  12. 8.2.5 Tianjin Tasly Saint Pharmaceuticals Recent Developments
  13. 8.3 Sun Pharmaceutical
  14. 8.3.1 Sun Pharmaceutical Company Information
  15. 8.3.2 Sun Pharmaceutical Business Overview
  16. 8.3.3 Sun Pharmaceutical Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sun Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio
  18. 8.3.5 Sun Pharmaceutical Recent Developments
  19. 8.4 Shanghai Pharmaceuticals
  20. 8.4.1 Shanghai Pharmaceuticals Company Information
  21. 8.4.2 Shanghai Pharmaceuticals Business Overview
  22. 8.4.3 Shanghai Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  24. 8.4.5 Shanghai Pharmaceuticals Recent Developments
  25. 8.5 Qilu Pharmaceutical
  26. 8.5.1 Qilu Pharmaceutical Company Information
  27. 8.5.2 Qilu Pharmaceutical Business Overview
  28. 8.5.3 Qilu Pharmaceutical Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Qilu Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio
  30. 8.5.5 Qilu Pharmaceutical Recent Developments
  31. 8.6 Kanghong Pharmaceuticals
  32. 8.6.1 Kanghong Pharmaceuticals Company Information
  33. 8.6.2 Kanghong Pharmaceuticals Business Overview
  34. 8.6.3 Kanghong Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Kanghong Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  36. 8.6.5 Kanghong Pharmaceuticals Recent Developments
  37. 8.7 Changzhou Siyao Pharmaceutical
  38. 8.7.1 Changzhou Siyao Pharmaceutical Company Information
  39. 8.7.2 Changzhou Siyao Pharmaceutical Business Overview
  40. 8.7.3 Changzhou Siyao Pharmaceutical Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Changzhou Siyao Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio
  42. 8.7.5 Changzhou Siyao Pharmaceutical Recent Developments
  43. 8.8 Wockhardt
  44. 8.8.1 Wockhardt Company Information
  45. 8.8.2 Wockhardt Business Overview
  46. 8.8.3 Wockhardt Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Wockhardt Non-benzodiazepine Hypnotics Product Portfolio
  48. 8.8.5 Wockhardt Recent Developments
  49. 8.9 Torrent Pharma
  50. 8.9.1 Torrent Pharma Company Information
  51. 8.9.2 Torrent Pharma Business Overview
  52. 8.9.3 Torrent Pharma Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Torrent Pharma Non-benzodiazepine Hypnotics Product Portfolio
  54. 8.9.5 Torrent Pharma Recent Developments
  55. 8.10 Teva Pharmaceuticals
  56. 8.10.1 Teva Pharmaceuticals Company Information
  57. 8.10.2 Teva Pharmaceuticals Business Overview
  58. 8.10.3 Teva Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  60. 8.10.5 Teva Pharmaceuticals Recent Developments
  61. 8.11 Tapi Teva
  62. 8.11.1 Tapi Teva Company Information
  63. 8.11.2 Tapi Teva Business Overview
  64. 8.11.3 Tapi Teva Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Tapi Teva Non-benzodiazepine Hypnotics Product Portfolio
  66. 8.11.5 Tapi Teva Recent Developments
  67. 8.12 Sanofi-aventis
  68. 8.12.1 Sanofi-aventis Company Information
  69. 8.12.2 Sanofi-aventis Business Overview
  70. 8.12.3 Sanofi-aventis Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi-aventis Non-benzodiazepine Hypnotics Product Portfolio
  72. 8.12.5 Sanofi-aventis Recent Developments
  73. 8.13 Northstar Rx
  74. 8.13.1 Northstar Rx Company Information
  75. 8.13.2 Northstar Rx Business Overview
  76. 8.13.3 Northstar Rx Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Northstar Rx Non-benzodiazepine Hypnotics Product Portfolio
  78. 8.13.5 Northstar Rx Recent Developments
  79. 8.14 Mylan Pharmaceuticals
  80. 8.14.1 Mylan Pharmaceuticals Company Information
  81. 8.14.2 Mylan Pharmaceuticals Business Overview
  82. 8.14.3 Mylan Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Mylan Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  84. 8.14.5 Mylan Pharmaceuticals Recent Developments
  85. 8.15 Kanghong Pharmaceutical
  86. 8.15.1 Kanghong Pharmaceutical Company Information
  87. 8.15.2 Kanghong Pharmaceutical Business Overview
  88. 8.15.3 Kanghong Pharmaceutical Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Kanghong Pharmaceutical Non-benzodiazepine Hypnotics Product Portfolio
  90. 8.15.5 Kanghong Pharmaceutical Recent Developments
  91. 8.16 Hikma Pharmaceuticals
  92. 8.16.1 Hikma Pharmaceuticals Company Information
  93. 8.16.2 Hikma Pharmaceuticals Business Overview
  94. 8.16.3 Hikma Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Hikma Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  96. 8.16.5 Hikma Pharmaceuticals Recent Developments
  97. 8.17 Glenmark Life Sciences
  98. 8.17.1 Glenmark Life Sciences Company Information
  99. 8.17.2 Glenmark Life Sciences Business Overview
  100. 8.17.3 Glenmark Life Sciences Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Glenmark Life Sciences Non-benzodiazepine Hypnotics Product Portfolio
  102. 8.17.5 Glenmark Life Sciences Recent Developments
  103. 8.18 Endo
  104. 8.18.1 Endo Company Information
  105. 8.18.2 Endo Business Overview
  106. 8.18.3 Endo Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Endo Non-benzodiazepine Hypnotics Product Portfolio
  108. 8.18.5 Endo Recent Developments
  109. 8.19 Dr. Reddy’s Laboratories
  110. 8.19.1 Dr. Reddy’s Laboratories Company Information
  111. 8.19.2 Dr. Reddy’s Laboratories Business Overview
  112. 8.19.3 Dr. Reddy’s Laboratories Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Dr. Reddy’s Laboratories Non-benzodiazepine Hypnotics Product Portfolio
  114. 8.19.5 Dr. Reddy’s Laboratories Recent Developments
  115. 8.20 Centaur Pharmaceuticals
  116. 8.20.1 Centaur Pharmaceuticals Company Information
  117. 8.20.2 Centaur Pharmaceuticals Business Overview
  118. 8.20.3 Centaur Pharmaceuticals Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Centaur Pharmaceuticals Non-benzodiazepine Hypnotics Product Portfolio
  120. 8.20.5 Centaur Pharmaceuticals Recent Developments
  121. 8.21 Apotex
  122. 8.21.1 Apotex Company Information
  123. 8.21.2 Apotex Business Overview
  124. 8.21.3 Apotex Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Apotex Non-benzodiazepine Hypnotics Product Portfolio
  126. 8.21.5 Apotex Recent Developments
  127. 8.22 Admiron Life
  128. 8.22.1 Admiron Life Company Information
  129. 8.22.2 Admiron Life Business Overview
  130. 8.22.3 Admiron Life Non-benzodiazepine Hypnotics Sales, Value and Gross Margin (2021-2026)
  131. 8.22.4 Admiron Life Non-benzodiazepine Hypnotics Product Portfolio
  132. 8.22.5 Admiron Life Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Non-benzodiazepine Hypnotics Value Chain Analysis
  2. 9.1.1 Non-benzodiazepine Hypnotics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Non-benzodiazepine Hypnotics Sales Mode & Process
  6. 9.2 Non-benzodiazepine Hypnotics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Non-benzodiazepine Hypnotics Distributors
  9. 9.2.3 Non-benzodiazepine Hypnotics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst